ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$274.88
3.08 (1.13%)
▲
5d:
+2.49%
30d:
-11.22%
90d:
+0.05%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 10.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 10.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$472.98
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$293.69
6.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $274.88, which is considered fair relative to its 30-day fair value range of $265.64 to $297.08. From a valuation perspective, the stock is trading at a discount (Forward PE: 28.0) compared to its historical average (38.9). Remarkably, the market is currently pricing in an annual earnings decline of 10.4% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a strong downtrend. The price is approaching resistance at $276.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $412.35 (+51.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is in a strong downtrend. The price is approaching resistance at $276.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $412.35 (+51.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$265.64 -
$297.08
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.7% below Wall St target ($412.35)
Trading Range Analysis
30-Day Trading Range
$265.64 -
$297.08
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$253.95
Resistance Level
$276.74
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.98
Wall Street Target
$412.35
(+51.7%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-10.4% cheaper
PE vs Historical
28.0 vs 38.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.4%
(market-implied from PE analysis)
1-Year Target
$244.62
(-10%)
2-Year Target
$220.16
(-19%)
3-Year Target
$198.14
(-27%)
3-Yr Target (if PE normalizes)
(PE: 28→39)
$275.51
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.0, Growth: 47.4%)
$870.72
(+220%)
Base:
(SPY PE: 21.8, Growth: 47.4%)
$677.87
(+149%)
Bear:
(PE: 18.5, Growth: 47.4%)
$576.19
(+112%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Forward PE: 43.86 | Forward EPS (Implied): $6.20
Bull Case
$328.20
(+21%)
Analyst growth 15.0%, PE expands to 46.1
Base Case
$271.80
(0%)
Market implied 0.0%, PE stable at 43.9
Bear Case
$207.93
(-24%)
Severe decline -15.0%, PE contracts to 39.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.0 to 38.9
Stabilization Target:
$377.93
(+39.0%)
PE Expansion Potential:
+39.0%
Share & Embed Analysis
Last updated: June 23, 2026 2:47 PM ET
Data refreshes hourly during market hours. Next update: 3:47 PM
Data refreshes hourly during market hours. Next update: 3:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |